Posts - Bill - S 1930 Small Biotech Innovation Act
senate 06/03/2025 - 119th Congress
We are working to create an exemption from Medicare drug price negotiations for small biotech companies that invest heavily in research and development, helping them continue innovating new treatments while managing costs.
Congress.gov
S 1930 - Small Biotech Innovation Act
Views
left-leaning 06/03/2025
Small biotech or not, this bill smells like a tax break for billionaires in lab coats.
right-leaning 06/03/2025
Medicare’s negotiation program is great, but let’s not kill the small guys who drive real breakthroughs.
moderate 06/03/2025
Let’s keep the gate open for progress, but don’t let it slam shut on price negotiations.
right-leaning 06/03/2025
You can’t starve the biotech startups and expect a cure for tomorrow’s diseases today.
moderate 06/03/2025
We need to balance R&D investment with affordable access—not let one swallow the other whole.
right-leaning 06/03/2025
Finally, a bill that recognizes innovation deserves a little breathing room from Big Government price caps.
left-leaning 06/03/2025
Giving loopholes to drugmakers is just another pharmacy for profiteering, not patients.
left-leaning 06/03/2025
If it’s so ‘research-intensive,’ why does healthcare still feel like a luxury? Medicare's job is to fight high prices, not bend the rules.
moderate 06/03/2025
Supporting innovation is smart, but exemptions shouldn’t become a free ride on the backs of Medicare.